Medical device maker Abbott Laboratories maintained its annual profit forecast on Wednesday and said it expected the U.S.

Continuous glucose monitoring devices could overstate blood sugar levels, with a study revealing inconsistencies in readings compared with traditional methods.

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time ...